Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Beijing, China
Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
J Neurointerv Surg. 2022 Mar;14(3):210-214. doi: 10.1136/neurintsurg-2021-017283. Epub 2021 Mar 15.
There remains major uncertainty regarding the optimal therapy for symptomatic nonacute extracranial vertebral artery occlusion (EVAO). Endovascular recanalization for EVAO is technically challenging, and limited data are available. This research aimed to report a multicenter clinical experience of endovascular recanalization for symptomatic nonacute EVAO and establish a novel angiographic classification.
From June 2011 to December 2019, 50 symptomatic nonacute EVAO patients treated with endovascular recanalization in three regional referral stroke centers were retrospectively analyzed. All patients were categorized into four groups based on the angiographic classification. The rates of technical success, periprocedural complications, any stroke or death within 1 month, and follow-up data were assessed.
The rates of technical success, periprocedural complications, and any stroke or death within 1 month were 86.0% (43/50), 12.0% (6/50), and 4.0% (2/50), respectively. The recanalization rates gradually decreased from Type A to Type D (100%, 94.7%, 80%, and 63.6%, respectively; P=0.007). The EVAO patients in the Type A group with tapered stump and short-segment occlusions showed excellent recanalization effects, with 100% technical success rates and no complications. Conversely, the lowest recanalization rate of 63.6% (7/11) and the highest periprocedural complication rate of 27.3% (3/11) were observed for the Type D group.
Endovascular recanalization for symptomatic nonacute EVAO is technically feasible, especially Type A EVAO patients, which can provide an alternative treatment option for recurrent vertebrobasilar ischemia despite optimal medical therapy. The angiographic categorization established in this study is conducive to the selection of suitable patients prior to treatment decision.
对于有症状的非急性颅外椎动脉闭塞(EVAO),最佳治疗方法仍存在很大的不确定性。EVAO 的血管内再通治疗技术上具有挑战性,且可用数据有限。本研究旨在报告三家区域转诊卒中中心采用血管内再通治疗有症状的非急性 EVAO 的多中心临床经验,并建立一种新的血管造影分类。
2011 年 6 月至 2019 年 12 月,回顾性分析了 3 家区域转诊卒中中心采用血管内再通治疗的 50 例有症状的非急性 EVAO 患者。所有患者均根据血管造影分类分为 4 组。评估了技术成功率、围手术期并发症、1 个月内任何卒中或死亡的发生率以及随访数据。
技术成功率、围手术期并发症和 1 个月内任何卒中或死亡的发生率分别为 86.0%(43/50)、12.0%(6/50)和 4.0%(2/50)。再通率从 A 型逐渐降至 D 型(分别为 100%、94.7%、80%和 63.6%;P=0.007)。A 型组中具有锥形残端和短节段闭塞的 EVAO 患者具有极好的再通效果,技术成功率为 100%,无并发症。相反,D 型组的再通率最低,为 63.6%(7/11),围手术期并发症发生率最高,为 27.3%(3/11)。
血管内再通治疗有症状的非急性 EVAO 在技术上是可行的,尤其是 A 型 EVAO 患者,即使在接受最佳药物治疗后,也可作为复发性椎基底动脉缺血的替代治疗选择。本研究建立的血管造影分类有利于在治疗决策前选择合适的患者。